Engimmune Therapeutics

Seed
engimmune.com Biotech & Healthcare
Total Funding $16M
Latest Round $16M Seed
Last Announced May 3, 2022
Investors Undisclosed
Decision Makers 3 Available

About Engimmune Therapeutics

Engimmune Therapeutics - Engineering the next-generation of soluble T cell receptor (TCR) therapies in oncology and immune-mediated disease.

Sectors & Market Categories

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Seed
Global Headquarters Undisclosed
Tracked Since Nov 8, 2026

Web & Domain Identity

Official Website engimmune.com
Domain Registered Date Undisclosed

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Company Profile

Company Milestones & Timeline

1 Events
  1. Capital Raise

    Raised $16,000,000 · Seed

    startupintros.com

Investors & Backers

Investor firms and individual backers were not publicly disclosed in available round filings for Engimmune Therapeutics.

Funding History

1 Round
Seed equity · May 3, 2022

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

Recently funded startups
New SaaS launches
Never pay twice for contacts